Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 6
Submit an article Journal homepage
274
Views
49
CrossRef citations to date
0
Altmetric
Review

Safety of obesity drugs

Frank L Greenway Louisiana State University System, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA. [email protected]
&
Mary K Caruso Louisiana State University System, Division of Human Ecology, Baton Rouge, Louisiana, USA
Pages 1083-1095 | Published online: 28 Oct 2005

Citations (49)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Caroline A. Andrew, Katherine H. Saunders, Alpana P. Shukla & Louis J. Aronne. (2019) Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. Expert Opinion on Pharmacotherapy 20:5, pages 585-593.
Read now
Giuseppe Derosa & Pamela Maffioli. (2012) Anti-obesity drugs: a review about their effects and their safety. Expert Opinion on Drug Safety 11:3, pages 459-471.
Read now
Louis J Aronne, Amanda G Powell & Caroline M Apovian. (2011) Emerging pharmacotherapy for obesity. Expert Opinion on Emerging Drugs 16:3, pages 587-596.
Read now
Sonja K Billes & Frank L Greenway. (2011) Combination therapy with naltrexone and bupropion for obesity. Expert Opinion on Pharmacotherapy 12:11, pages 1813-1826.
Read now
Harold E Bays. (2011) Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Review of Cardiovascular Therapy 9:3, pages 265-277.
Read now
Harold Bays. (2010) Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Review of Cardiovascular Therapy 8:12, pages 1777-1801.
Read now
Patrik Roser, Franz X. Vollenweider & Wolfram Kawohl. (2010) Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. The World Journal of Biological Psychiatry 11:2-2, pages 208-219.
Read now
Harold E Bays. (2009) Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease. Expert Review of Cardiovascular Therapy 7:11, pages 1429-1445.
Read now
David R Janero & Alexandros Makriyannis. (2009) Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs 14:1, pages 43-65.
Read now
Nir Barak. (2008) Betahistine: what's new on the agenda?. Expert Opinion on Investigational Drugs 17:5, pages 795-804.
Read now
Frank Greenway & Mary Katherine Caruso. (2007) The safety of obesity drugs – authors' response. Expert Opinion on Drug Safety 6:5, pages 477-478.
Read now
Luc F Van Gaal, André J Scheen & Xavier Formiguera. (2007) The safety of obesity drugs – correspondence. Expert Opinion on Drug Safety 6:5, pages 475-476.
Read now

Articles from other publishers (37)

Ji Li, Xuedong Wang, Xiangyu Meng, Xin Zhou, Han Huang, Yi Feng, Yujie Fu, Xinxin Liu & Bo Yu. (2023) Geraniin targeting CaMKK2 inhibits lipid accumulation in 3T3-L1 adipocytes by suppressing lipogenesis. Chemico-Biological Interactions 372, pages 110364.
Crossref
Eduardo Grunvald, Raj Shah, Ruben Hernaez, Apoorva Krishna Chandar, Octavia Pickett-Blakely, Levi M. Teigen, Tasma Harindhanavudhi, Shahnaz Sultan, Siddharth Singh & Perica Davitkov. (2022) AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology 163:5, pages 1198-1225.
Crossref
Dagam Jeong & Ronny Priefer. (2022) Anti-obesity weight loss medications: Short-term and long-term use. Life Sciences 306, pages 120825.
Crossref
Ki-Hyo Jang & Mi-Ja Kim. (2022) A mixture of poly-γ-glutamic acid and levan ameliorates obesity in high fat diet-induced mice. Food Science and Biotechnology 31:3, pages 349-356.
Crossref
Jin Ree, Jun Il Kim, Chang Won Lee, Jisun Lee, Hyeon Jeong Kim, Seong Cheol Kim, Jae Kyung Sohng & Yong Il Park. (2021) Quinizarin suppresses the differentiation of adipocytes and lipogenesis in vitro and in vivo via downregulation of C/EBP-beta/SREBP pathway. Life Sciences 287, pages 120131.
Crossref
Xinxin Liu, Ying Lv, Mengyu Zheng, Li Yin, Xiqing Wang, Yujie Fu, Bo Yu & Ji Li. (2021) Polyphenols from blue honeysuckle (Lonicera caerulea var. edulis) berry inhibit lipid accumulation in adipocytes by suppressing lipogenesis. Journal of Ethnopharmacology 279, pages 114403.
Crossref
Daniela S. Valdes, Daniel So, Paul A. Gill & Nicole J. Kellow. (2021) Effect of Dietary Acetic Acid Supplementation on Plasma Glucose, Lipid Profiles, and Body Mass Index in Human Adults: A Systematic Review and Meta-analysis. Journal of the Academy of Nutrition and Dietetics 121:5, pages 895-914.
Crossref
Ken Fujioka & Samantha R. Harris. (2020) Barriers and Solutions for Prescribing Obesity Pharmacotherapy. Endocrinology and Metabolism Clinics of North America 49:2, pages 303-314.
Crossref
Gagik R. Galstyan, Ekaterina A. Shestakova & Igor A. Sklyanik. (2017) Obesity and type 2 diabetes: can we find a compromised treatment solution?. Diabetes mellitus 20:4, pages 270-278.
Crossref
M. MacMillan, K. Cummins & K. Fujioka. (2016) What weight loss treatment options do geriatric patients with overweight and obesity want to consider?. Obesity Science & Practice 2:4, pages 477-482.
Crossref
Jinmei Li, Lili Ding, Baoliang Song, Xu Xiao, Meng Qi, Qiaoling Yang, Qiming Yang, Xiaowen Tang, Zhengtao Wang & Li Yang. (2016) Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway. European Journal of Pharmacology 770, pages 99-109.
Crossref
Karran A. Phillips, David H. Epstein & Kenzie L. Preston. (2014) Psychostimulant addiction treatment. Neuropharmacology 87, pages 150-160.
Crossref
Melvin George, Muthukumar Rajaram & Elangovan Shanmugam. (2013) New and Emerging Drug Molecules Against Obesity. Journal of Cardiovascular Pharmacology and Therapeutics 19:1, pages 65-76.
Crossref
C K Boughton & K G Murphy. (2013) Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. British Journal of Pharmacology 170:7, pages 1333-1348.
Crossref
Shen-Chieh Chang & Winston W. Shen. (2013) Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications. Journal of Experimental & Clinical Medicine 5:6, pages 210-216.
Crossref
Yong Pil Hwang, Jae Ho Choi, Hyung Gyun Kim, Hyun-Sun Lee, Young Chul Chung & Hye Gwang Jeong. (2013) Saponins from Platycodon grandiflorum inhibit hepatic lipogenesis through induction of SIRT1 and activation of AMP-activated protein kinase in high-glucose-induced HepG2 cells. Food Chemistry 140:1-2, pages 115-123.
Crossref
Harold E. Bays, Peter P. Toth, Penny M. Kris-Etherton, Nicola Abate, Louis J. Aronne, W. Virgil Brown, J. Michael Gonzalez-Campoy, Steven R. Jones, Rekha Kumar, Ralph La Forge & Varman T. Samuel. (2013) Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology 7:4, pages 304-383.
Crossref
Hoyoung An, Hyunjoo Sohn & Seockhoon Chung. (2013) Phentermine, Sibutramine and Affective Disorders. Clinical Psychopharmacology and Neuroscience 11:1, pages 7-12.
Crossref
Thing-Fong Tzeng, Hung-Jen Lu, Shorong-Shii Liou, Chia Ju Chang & I-Min Liu. (2013) Reduction of lipid accumulation in white adipose tissues by Cassia tora (Leguminosae) seed extract is associated with AMPK activation. Food Chemistry 136:2, pages 1086-1094.
Crossref
Thing-Fong Tzeng, Hung-Jen Lu, Shorong-Shii Liou, Chia Ju Chang & I-Min Liu. (2012) Emodin, a Naturally Occurring Anthraquinone Derivative, Ameliorates Dyslipidemia by Activating AMP-Activated Protein Kinase in High-Fat-Diet-Fed Rats. Evidence-Based Complementary and Alternative Medicine 2012, pages 1-9.
Crossref
Ed J. Hendricks, Frank L. Greenway, Eric C. Westman & Alok K. Gupta. (2012) Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity. Obesity 19:12, pages 2351-2360.
Crossref
Pradeep J. Nathan, Barry V. O’Neill, Antonella Napolitano & Edward T. Bullmore. (2011) Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs. CNS Neuroscience & Therapeutics 17:5, pages 490-505.
Crossref
André J. Scheen. (2011) Sibutramine on Cardiovascular Outcome. Diabetes Care 34:Supplement_2, pages S114-S119.
Crossref
A.J. Scheen. (2010) Cardiovascular Risk-Benefit Profile of Sibutramine. American Journal Cardiovascular Drugs 10:5, pages 321-334.
Crossref
Ken Fujioka & Nitasha Bakhru. (2010) Office‐based Management of Obesity. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:5, pages 466-471.
Crossref
André J. Scheen. (2010) Controversy about the Cardiovascular Safety of Sibutramine. Drug Safety 33:7, pages 615-618.
Crossref
Jamie R. Robinson & Kevin D. Niswender. (2009) What are the risks and the benefits of current and emerging weight-loss medications?. Current Diabetes Reports 9:5, pages 368-375.
Crossref
C. S. Elangbam. (2009) Review Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. Veterinary Pathology 46:1, pages 10-24.
Crossref
Aldo P Maggioni, Ian Caterson, Walmir Coutinho, Nick Finer, Luc Van Gaal, Arya M Sharma, Christian Torp-Pedersen, Peter Bacher, Gillian Shepherd, Rui Sun & Philip James. (2008) Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Journal of Cardiovascular Pharmacology 52:5, pages 393-402.
Crossref
Heiner K. Berthold, Susanne Unverdorben, Ralf Degenhardt, Martin Unverdorben & Ioanna Gouni‐Berthold. (2012) Effect of a Cellulose‐containing Weight‐loss Supplement on Gastric Emptying and Sensory Functions. Obesity 16:10, pages 2272-2280.
Crossref
Alma Fulurija, Thomas A. Lutz, Katja Sladko, Melania Osto, Peter Y. Wielinga, Martin F. Bachmann & Philippe Saudan. (2008) Vaccination against GIP for the Treatment of Obesity. PLoS ONE 3:9, pages e3163.
Crossref
C. A. KIRK, J. F. BOUCHER, S. J. SUNDERLAND & J. A. WREN. (2007) Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs. Journal of Veterinary Pharmacology and Therapeutics 30:s1, pages 66-72.
Crossref
Frank Greenway & Alok Gupta. 2007. Obesity. Obesity 199 217 .
Frank Greenway & Jolene Zheng. (2016) Electrical Stimulation as Treatment for Obesity and Diabetes. Journal of Diabetes Science and Technology 1:2, pages 251-259.
Crossref
Eve A. Roberts. (2007) Non-alcoholic Steatohepatitis in Children. Clinics in Liver Disease 11:1, pages 155-172.
Crossref
Andrew J. Krentz. (2006) Prevention of Cardiovascular Complications of the Metabolic Syndrome: Focus on Pharmacotherapy. Metabolic Syndrome and Related Disorders 4:4, pages 328-341.
Crossref
Helmy M. Siragy. (2006) Clinical trials report. Current Hypertension Reports 8:4, pages 275-276.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.